- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Severe obesity
- Meeting Date: November 2023
- Public Summary Document (PSD) November 2023 PBAC Meeting - (PDF 819KB)
- Public Summary Document (PSD) November 2023 PBAC Meeting - (Word 167KB)
Semaglutide – November 2023
Semaglutide: Injection 0.25 mg in 0.5 mL pre-filled single dose pen, Injection 0.5 mg in 0.5 mL pre-filled single dose pen, Injection 1.0 mg in 0.5 mg pre-filled single dose pen, Injection 1.7 mg in 0.75 mL pre-filled single dose pen, Injection 2.4 mg in 0.75 mL pre-filled single dose pen; Wegovy®
Last updated
1 March 2024
